L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

The first report of detecting the blaSIM-2 gene and determining the complete sequence of the SIM-encoding plasmid F. Sun, D. Zhou, Q. Wang, J. Feng,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Reduced turn-around time for Mycobacterium tuberculosis drug susceptibility testing with a proportional agar microplate assay V.A.T. Nguyen, H.Q. Nguyen,

Patterns of delays in diagnosis amongst patients with smear-positive pulmonary tuberculosis at a teaching hospital in Turkey E. Okur, A. Yilmaz, A. Saygi,

Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm S.O. Simons, T. van der Laan,

High prevalence of azithromycin resistance to Treponema pallidum in geographically different areas in China X.-S. Chen, Y.-P. Yin, W.-H. Wei, H.-C. Wang,

G. Catho, S. Couraud, S. Grard, A. Bouaziz, A. Sénéchal, F. Valour, T

Gut bacterial microbiota and obesity

I.J. Schalk Clinical Microbiology and Infection

Salvage therapy for multidrug-resistant tuberculosis

Incidence and outcome of Staphylococcus aureus endocarditis—a 10-year single-centre northern European experience H. Asgeirsson, A. Thalme, M. Kristjansson,

Multidrug-resistant tuberculosis and migration to Europe

D. Khalil, M. Hultin, M.U. Rashid, B. Lund

Control of multidrug-resistant Gram-negative bacteria in low- and middle-income countries—high impact interventions without much resources N. Singh,

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications T.-L. Liao, Y.-M.

Migrant health—a cause for concern?

Mycobacterial peritonitis: difference between non-tuberculous mycobacteria and Mycobacterium tuberculosis C.-C. Shu, J.-T. Wang, J.-Y. Wang, C.-J. Yu,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

Screening of migrants for tuberculosis identifies patients with multidrug-resistant tuberculosis but is not sufficient P. Helbling Clinical Microbiology.

Rapid and accurate detection of rifampin and isoniazid-resistant Mycobacterium tuberculosis using an oligonucleotide array W.-L. Huang, Z.-J. Hsu, T.C.

Paradoxical immune reconstitution inflammatory syndrome associated with cryptococcal meningitis in China: a 5-year retrospective cohort study S. Yan,

Whole genome analysis of Mycobacterium tuberculosis isolates from recurrent episodes of tuberculosis, Finland, 1995–2013 V. Korhonen, P.W. Smit, M. Haanperä,

GidB mutation as a phylogenetic marker for Q1 cluster Mycobacterium tuberculosis isolates and intermediate-level streptomycin resistance determinant in.

A. F. Simonetti, C. Garcia-Vidal, D. Viasus, D. García-Somoza, J

Risk factors and outcome for colistin-resistant Acinetobacter nosocomialis bacteraemia in patients without previous colistin exposure Y.-C. Wang, Y.-T.

Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice? T. Coenye, D. Goeres, F. Van Bambeke, T. Bjarnsholt

Performance of microscopic observation drug susceptibility for the rapid diagnosis of tuberculosis and detection of drug resistance in Bamako, Mali M.

H. Adibhesami, M. Douraghi, M. Rahbar, A. Abdollahi

Vector control: a cornerstone in the malaria elimination campaign

The first report of detecting the blaSIM-2 gene and determining the complete sequence of the SIM-encoding plasmid F. Sun, D. Zhou, Q. Wang, J. Feng,

Z. Jia, S. Chen, C. Hao, Y. Huang, Z. Liu, A. Pan, R. Liao, X. Wang, Z

Characterization of Mycobacterium tuberculosis isolated from cancer patients with suspected tuberculosis infection in Egypt: identification, prevalence,

Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination M.-R. Lee,

C. Fabrizio, A. Procopio Clinical Microbiology and Infection

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Salvage therapy for multidrug-resistant tuberculosis

Clinical Epidemiology and Global Health

Metagenomics and probiotics

Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving.

M. Aires-de-Sousa Clinical Microbiology and Infection

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia E.V. Lemos, F.P.

Detection of Wolbachia genes in a patient with non-Hodgkin's lymphoma

J. Garau Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

Tuberculosis drug-resistance in Lisbon, Portugal: a 6-year overview

Systematic review of antibiotic consumption in acute care hospitals

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci H.L. DuPont, Z.-D. Jiang Clinical Microbiology.

T. Schön, P. Miotto, C.U. Köser, M. Viveiros, E. Böttger, E. Cambau

Tuberculosis transmission patterns among Spanish-born and foreign-born populations in the city of Barcelona S. Borrell, G. Tudó, E. Rey, J. González-Martín

C. Tamalet, P. Colson, E. Decroly, C. Dhiver, I. Ravaux, A. Stein, D

Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,

Increased in vitro fitness of multi- and extensively drug-resistant F15/LAM4/KZN strains of Mycobacterium tuberculosis C.C. Naidoo, M. Pillay Clinical.

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Z. Erjavec, H. Kluin-Nelemans, P.E. Verweij

Survival of rhinoviruses on human fingers

Virology: a scientific discipline facing new challenges

R. Khatib, G. Simeunovic, M. Sharma, M. G. Fakih, L. B. Johnson, L

Enterococcal isolates carrying the novel oxazolidinone resistance gene optrA from hospitals in Zhejiang, Guangdong, and Henan, China, 2010–2014 J. Cai,

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Acquisition of second-line drug resistance and extensive drug resistance during recent transmission of Mycobacterium tuberculosis in rural China Y. Hu,

Impact of antibiotic restrictions: the patient's perspective

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009–2013 L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X. Wang, Z. Jia Clinical Microbiology and Infection Volume 24, Issue 4, Pages 381-388 (April 2018) DOI: 10.1016/j.cmi.2017.07.008 Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 1 Inclusion of MDR-TB patients in analysis. MDR-TB, multidrug-resistant tuberculosis. Clinical Microbiology and Infection 2018 24, 381-388DOI: (10.1016/j.cmi.2017.07.008) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 2 Drug resistance among 159 MDR-TB patients whose second-line drug-susceptibility testing results were available. E, ethambutol; H, isoniazid; Km, kanamycin; MDR, multidrug resistance; MDR-FL, TB with resistance to isoniazid and rifampin, but not any second-line drugs; MDR-TB, multidrug-resistant tuberculosis; Ofx, ofloxacin; pre-XDR-TB, TB with resistance to isoniazid, rifampin and either ofloxacin or kanamycin; R, rifampicin; S, streptomycin; TB, tuberculosis; XDR, extensively drug resistant (TB with resistance to isoniazid, rifampin, and both ofloxacin and kanamycin). Clinical Microbiology and Infection 2018 24, 381-388DOI: (10.1016/j.cmi.2017.07.008) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 3 Time to poor treatment outcome of MDR-TB by drug resistance pattern. Poor treatment outcome was defined as treatment failure, death or death. Log-rank test p value for trend of survivor functions = 0.0018. MDR, multidrug resistant; MDR-FL, TB with resistance to isoniazid and rifampin, but not any second-line drugs; pre-XDR-TB, TB with resistance to isoniazid, rifampin and either ofloxacin or kanamycin; TB, tuberculosis; XDR, extensively drug resistant (TB with resistance to isoniazid, rifampin, and both ofloxacin and kanamycin). Clinical Microbiology and Infection 2018 24, 381-388DOI: (10.1016/j.cmi.2017.07.008) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions